| scholarly article | Q13442814 |
| P2093 | author name string | Dongwei Zhang | |
| Naoto T Ueno | |||
| P2860 | cites work | Cancer statistics, 2010 | Q27860525 |
| Cancer metastasis: building a framework | Q29616783 | ||
| Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. | Q34400238 | ||
| Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer | Q35007782 | ||
| Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas | Q35984566 | ||
| Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity | Q37015793 | ||
| Triple-negative breast cancer--current status and future directions | Q37630082 | ||
| Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype | Q40012189 | ||
| Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. | Q40118510 | ||
| NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. | Q40252191 | ||
| Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis | Q40590311 | ||
| Expression of the integrin alpha 4 beta 1 on melanoma cells can inhibit the invasive stage of metastasis formation. | Q46189108 | ||
| Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy | Q46610633 | ||
| Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models | Q46857082 | ||
| Feeder-Free Monolayer Cultures of Human Embryonic Stem Cells Express an Epithelial Plasma Membrane Protein Profile | Q57666189 | ||
| P304 | page(s) | 324-328 | |
| P577 | publication date | 2011-05-28 | |
| P1433 | published in | Journal of Cancer | Q6294901 |
| P1476 | title | Targeting EGFR in Triple Negative Breast Cancer | |
| P478 | volume | 2 |
| Q24626194 | A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer |
| Q47151712 | APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. |
| Q47100468 | Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping |
| Q91641922 | Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing |
| Q49500666 | Cigarette smoke-induced EGFR activation promotes epithelial mesenchymal migration of human retinal pigment epithelial cells through regulation of the FAK-mediated Syk/Src pathway |
| Q48551091 | Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer |
| Q40983668 | Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. |
| Q33802940 | Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy |
| Q29248648 | Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer |
| Q92347514 | Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy |
| Q64072752 | Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis |
| Q34365738 | EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer |
| Q92252053 | Effective treatment of cancer metastasis using a dual-ligand nanoparticle |
| Q36026041 | Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas |
| Q36947703 | Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway |
| Q34023653 | Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy |
| Q43912153 | Fatty acid synthase affects expression of ErbB receptors in epithelial to mesenchymal transition of breast cancer cells and invasive ductal carcinoma |
| Q34485539 | Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients |
| Q37226242 | Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database |
| Q97523308 | High formin binding protein 17 (FBP17) expression indicates poor differentiation and invasiveness of ductal carcinomas |
| Q46264415 | Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells |
| Q42315804 | Hypoxia-inducible factor prolyl hydroxylase 2 (PHD2) is a direct regulator of epidermal growth factor receptor (EGFR) signaling in breast cancer. |
| Q89454919 | Identification of synergistic drug combinations using breast cancer patient-derived xenografts |
| Q34476337 | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? |
| Q34439395 | Linking signaling pathways to transcriptional programs in breast cancer. |
| Q47974736 | Measurement of Epidermal Growth Factor Receptor-Derived Signals Within Plasma Membrane Clathrin Structures |
| Q42513445 | Metalloprotease-dependent activation of EGFR modulates CD44+/CD24- populations in triple negative breast cancer cells through the MEK/ERK pathway. |
| Q49269166 | Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1. |
| Q64249080 | Multi-Omic Data Interpretation to Repurpose Subtype Specific Drug Candidates for Breast Cancer |
| Q54978331 | NOTCH3 inactivation increases triple negative breast cancer sensitivity to gefitinib by promoting EGFR tyrosine dephosphorylation and its intracellular arrest. |
| Q47242275 | One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDA-MB-231 cells. |
| Q64945759 | Pan-cancer analysis identifies telomerase-associated signatures and cancer subtypes. |
| Q42700663 | Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype |
| Q57285764 | Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition |
| Q37520289 | Radiation-enhanced therapeutic targeting of galectin-1 enriched malignant stroma in triple negative breast cancer |
| Q91967488 | Reversal of EGFR inhibitors' resistance by co-delivering EGFR and integrin αvβ3 inhibitors with nanoparticles in non-small cell lung cancer |
| Q36428439 | SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer |
| Q50969676 | Significance of EGFR Expression in Circulating Tumor Cells. |
| Q34774884 | Standard of care and promising new agents for triple negative metastatic breast cancer |
| Q39088864 | Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer |
| Q27679683 | Structural and Functional Studies on the Interaction of Adenovirus Fiber Knobs and Desmoglein 2 |
| Q36293047 | Systematic Identification and Assessment of Therapeutic Targets for Breast Cancer Based on Genome-Wide RNA Interference Transcriptomes |
| Q36688302 | Tamoxifen Action in ER-Negative Breast Cancer |
| Q28118941 | The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer |
| Q64976310 | The TGFα-EGFR-Akt signaling axis plays a role in enhancing proinflammatory chemokines in triple-negative breast cancer cells. |
| Q36165932 | The efficacy of betulinic acid in triple-negative breast cancer |
| Q37304764 | The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer |
| Q28081591 | Therapeutic targets of triple-negative breast cancer: a review |
| Q35095843 | Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis. |
| Q33913833 | hMAGEA2 promotes progression of breast cancer by regulating Akt and Erk1/2 pathways |
Search more.